Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 7, 2025 deadline [2] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, and that public statements made by the defendants were materially false and misleading [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Coty, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Financial Performance - Coty disclosed its financial results for the full fiscal year of 2025 and its fourth quarter in a Current Report on Form 8-K filed on August 20, 2025 [3]. - The Chief Financial Officer of Coty attributed sluggish sales to several factors, including value-seeking behavior, innovation fatigue among consumers, and changes in anti-theft and immigration policies [3]. Group 2: Stock Market Reaction - Following the news of Coty's financial performance, the company's stock price fell by $1.05 per share, representing a decline of 21.6%, closing at $3.81 per share on August 21, 2025 [4]. Group 3: Legal Action and Investor Rights - Investors who purchased Coty securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5].

Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Details - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries [4] - The misleading statements led to investors suffering damages when the true details were revealed [4] Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions, as many firms may not have the necessary experience [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [3]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Semler Scientific, Inc. securities about the lead plaintiff deadline for a securities class action lawsuit, emphasizing the potential for compensation without upfront costs for eligible investors [1][2]. Group 1: Class Action Details - The class action pertains to securities purchased between March 10, 2021, and April 15, 2025, with a lead plaintiff deadline set for October 28, 2025 [1]. - Investors who wish to join the class action can do so through a provided link or by contacting the firm directly [3][6]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [3]. Group 2: Legal Background - The lawsuit alleges that Semler Scientific made materially false and misleading statements and failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act [5]. - The claims suggest that the defendants' public statements were misleading, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that the defendants made false or misleading statements regarding the efficacy of their product compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities during the specified class period of the upcoming lead plaintiff deadline on November 7, 2025, and the potential for compensation through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Savara securities between March 7, 2024, and May 23, 2025, may be eligible for compensation without upfront costs [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success and recognition in the field [3]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [3]. Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4]. - It is claimed that these misrepresentations led to investor damages when the true details became public, indicating a potential need for Savara to raise additional capital due to delays in regulatory approval [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 15, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and securing over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5]. - Specific claims include that Baxter was aware of multiple malfunctions and injuries related to the device but did not take adequate remedial measures, resulting in misleading statements about the product's safety and efficacy [5].

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW) [1] Group 1 - The investigation is focused on the actions of the company's directors and officers, suggesting possible legal implications for Edwards Lifesciences [1] - Investors who own shares of Edwards stock are encouraged to seek more information through Rosen Law Firm's website or contact details [2] - Rosen Law Firm emphasizes its experience and success in handling securities class actions, highlighting its track record and recognition in the legal field [3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Tandem Diabetes Care on August 7, 2025, regarding a voluntary medical device correction for select t:slim X2 insulin pumps, which indicated a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a significant stock price drop of 18.2% following the release of disappointing first-quarter results, which included a loss of 69 cents per share compared to a net loss of 15 cents per share in the previous year [3]. - Shareholders who purchased America's Car-Mart, Inc. securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and consistently ranking among the top firms in this area since 2013 [4].